Molecular Mechanisms And Functional Consequences - Understanding Endocrine Tumorigenesis
Funder
National Health and Medical Research Council
Funding Amount
$124,530.00
Summary
A/Prof Marsh is focused on discovering the causes of both inherited and non-inherited endocrine tumours, translating this knowledge into medical practice for the improved diagnosis of cancer and using this knowledge to highlight new therapeutic options for people who have cancer. She is internationally recognised for her work on a protein linked to the development of parathyroid cancer and is working towards improving our understanding of women’s cancers.
A Solution To The Parathyroid Gland Secretion Problem
Funder
National Health and Medical Research Council
Funding Amount
$508,003.00
Summary
Parathyroid hormone is the master hormone regulator of whole body calcium metabolism and a powerful new treatment for osteoporosis but the mechanism by which its natural secretion is controlled has never been solved. In this project we will apply new insights and advanced technical approaches to resolve this most fundamental question of calcium homeostasis, namely how parathyroid hormone secretion is controlled.
The Roles Of EZH2 And FOXO1A In CNS-PNET Pathogenesis.
Funder
National Health and Medical Research Council
Funding Amount
$467,517.00
Summary
Although CNS-PNETs are the most common embryonal CNS tumours of childhood and cause significant mortality and morbidity, there is a very limited understanding of the pathogenesis of this aggressive disease. This situation is a major handicap to the development of more specific and effective therapies. While a better understanding of the fundamental pathology of CNS-PNETs will have immediate diagnostic implications, the elucidation of the biochemical pathways that are disrupted in these tumours w ....Although CNS-PNETs are the most common embryonal CNS tumours of childhood and cause significant mortality and morbidity, there is a very limited understanding of the pathogenesis of this aggressive disease. This situation is a major handicap to the development of more specific and effective therapies. While a better understanding of the fundamental pathology of CNS-PNETs will have immediate diagnostic implications, the elucidation of the biochemical pathways that are disrupted in these tumours will facilitate the design of new drugs that are specifically directed towards the critical proteins in these pathways. The identification of specific genes and-or pathways that are deregulated in CNS-PNET cells is essential for the development of safer, more directed, and more effective therapies that are urgently required for the treatment of those with this devastating disease.Read moreRead less
Does Teriparatide Reverse Osteonecrosis Of The Jaw In Patients With Cancer? A Randomised, Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$357,412.00
Summary
Osteonecrosis of the jaw (ONJ) is debilitating and associated with drugs that increase bone strength and reduce the bone remodeling rate (bisphosphonates or denosumab). Up to 15% of patients with bone marrow cancer and 1 out of 952 patients with osteoporosis treated with bisphosphonates may get ONJ. This 8-week trial of subcutaneous teriparatide (a hormone that forms new bone) or placebo injections aims to promote resolution of ONJ, measured clinically and by x-ray, and improve quality of life.